RxDoctor Payments Data

K Gopalakrishna, MD

Infectious Disease · Cleveland, OHNPI 1295769735

Payments from drug & device makers

$1,680in general payments, 2019–2025

Across 73 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$323
  • Boehringer Ingelheim$278
  • Gilead$238
  • Johnson & Johnson$214
  • AbbVie$161
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$138
  • plus $327 from 8 others

What the payments were for

  • Food & beverage$1,39783%
  • Education$28317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,680 in reported general payments places this provider in the 65th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$76,229
Medicare patients
385
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen128$518,655
BiktarvyBictegrav/Emtricit/Tenofov Ala73$279,098
DescovyEmtricitabine/Tenofov Alafenam24$56,692
PrezcobixDarunavir/Cobicistat21$51,759
DovatoDolutegravir Sodium/Lamivudine14$48,295
TriumeqAbacavir/Dolutegravir/Lamivudi13$47,527
Caspofungin Acetate14$25,737
ErtapenemErtapenem Sodium29$16,087
Maraviroc13$9,141
Nevirapine ErNevirapine13$2,865
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam14$2,549
Doxycycline Monohydrate47$2,427
Lamivudine-ZidovudineLamivudine/Zidovudine23$1,960
Meropenem13$1,855
Cefepime Hcl20$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$238$854,445225 claims
Johnson & JohnsonPrezcobix$214$51,75921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →